About: Alefacept     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. (en)
http://linked.open...generalReferences
  • # Koo JY, Bagel J, Sweetser MT, Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006 Jul-Aug;5(7):623-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16865867 # Krell JM: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. 2006 Jun;54(6):1099-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16713481 # Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006 Apr;5(4):339-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16673801 # American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Alefacept; [updated 2014 Jan 30; cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=9&sid=78010ea4-6f9c-4d5a-a7df-a148b3891321%40sessionmgr110&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232900 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
  • withdrawn (en)
http://linked.open...drugbank/halfLife
  • ~270 hours (en)
http://linked.open...ugbank/indication
  • As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis (en)
sameAs
Title
  • Alefacept (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen. (en)
http://linked.open...drugbank/packager
http://linked.open.../drugbank/synonym
  • ASP0485 (en)
http://linked.open...drugbank/toxicity
  • While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk. (en)
http://linked.open.../drug/hasAHFSCode
http://linked.open...y/mesh/hasConcept
foaf:page
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...l/drug/hasATCCode
http://linked.open...ugbank/absorption
  • Bioavailability after IM administration is 63%. (en)
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 222535-22-0 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...gbank/containedIn
http://linked.open...nk/Hydrophobicity
http://linked.open...Isoelectric-Point
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 26 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software